Physician profile
Stan Golin
NPI 1942281035
$8,925.08
in general payments reported to CMS, 2019-2025
14 companies · $6,494 in 2025
The $6,494 reported for 2025 was more than what 95% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $150 · 2020: $550 · 2021: $671 · 2022: $383 · 2023: $155 · 2024: $521 · 2025: $6,494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $5,817 · Food and Beverage: $1,354.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $5,816.98 |
| Food and Beverage | $1,353.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioprotect Medical, INC. | $6,666.79 | 2024-2025 | Bioprotect Balloon Implant System |
| Blue Earth Diagnostics | $1,306.00 | 2019-2023 | |
| Teleflex LLC | $182.13 | 2024 | |
| Palette Life Sciences, INC. | $180.00 | 2022 | |
| Myovant Sciences INC. | $129.17 | 2021-2022 | |
| Isoray, INC | $85.74 | 2022 | |
| Astellas Pharma US INC | $77.60 | 2021 | |
| Accuray Incorporated | $61.75 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $53.64 | 2019-2025 | |
| Bard Peripheral Vascular, INC. | $43.74 | 2024-2025 | Model 200 Theraseed Palladium-103 In Readylink |
| Boston Scientific Corporation | $37.77 | 2023 | Spaceoar Vue System - 10ml |
| Dendreon Pharmaceuticals LLC | $37.27 | 2025 | Provenge |
| Myriad Genetic Laboratories, INC. | $35.66 | 2025 | Prolaris |
| Progenics Pharmaceuticals, INC. | $27.82 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stan Golin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.